Longitudinal algorithm may detect ovarian cancer earlier

Longitudinal algorithm may detect ovarian cancer earlier
Compared with a single-threshold rule, a parametric empirical Bayes longitudinal screening algorithm can identify ovarian cancer earlier and at a lower concentration of CA125, according to research published online Dec. 17 in the Journal of Clinical Oncology.

(HealthDay)—Compared with a single-threshold (ST) rule, a parametric empirical Bayes (PEB) longitudinal screening algorithm can identify ovarian cancer earlier and at a lower concentration of CA125, according to research published online Dec. 17 in the Journal of Clinical Oncology.

Charles W. Drescher, M.D., of the Fred Hutchinson Cancer Research Center in Seattle, and colleagues compared an ST rule with a PEB longitudinal screening algorithm in a retrospective evaluation of preclinical CA125 values measured annually in 44 participants with incident from the Prostate Lung Colorectal and Ovarian (PLCO) Cancer Screening Trial.

The researchers found that, in many cases, ovarian cancer was detected earlier using the PEB algorithm, compared to using an ST rule. At a specificity of 99 percent, corresponding to an ST rule CA125 cut-off of ≥35 U/mL used in the PLCO trial, use of the PEB algorithm would have identified 20 percent of cases earlier. The PEB indicated abnormal CA125 values among these cases 10 months earlier and at a lower CA125 concentration (42 percent lower; 20 U/mL) than an ST rule cut-off. As the specificity of screening was reduced, there was an increase in the proportion of cases detected earlier by PEB.

"Our results demonstrated that, for ovarian by using , the PEB longitudinal algorithm detected ovarian cancer earlier than an ST rule in a statistically significant and meaningful proportion of cases," the authors write. "This observation was consistent across a range of specificities relevant for a first-line test in a multimodal ."

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Assessing lead time of selected ovarian cancer biomarkers

Dec 31, 2009

Concentrations of the biomarkers CA125, human epididymis protein 4 (HE4), and mesothelin began to rise 3 years before clinical diagnosis of ovarian cancer, according to a new study published online December 30 in the Journal of ...

FDA clears biomarker test for ovarian cancer

Sep 06, 2011

Approval last week by U.S. Food and Drug Administration (FDA) clears the path for nationwide use of tools that show the greatest specificity in estimating the risk of ovarian cancer in women with a pelvic mass.

Recommended for you

Blood biomarker may detect lung cancer

6 hours ago

A new study shows that patients with stage I to stage III non-small cell lung cancer have different metabolite profiles in their blood than those of patients who are at risk but do not have lung cancer. The study abstract ...

ACG: Recent increase in incidence of young-onset CRC

22 hours ago

(HealthDay)—The incidence of young-onset colorectal cancer (CRC) is increasing, and the disease is more aggressive pathologically. These findings are being presented at the annual meeting of the American ...

User comments